U
Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
D
Sell
12/20/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 12/20/2024 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 12/20/2024 due to an increase in the volatility index.
E
Sell
11/29/2024Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 11/29/2024 due to a decline in the volatility index and growth index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 11/29/2024 due to a decline in the volatility index and growth index.
D
Sell
6/18/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 6/18/2024 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 6/18/2024 due to an increase in the volatility index and total return index.
E
Sell
6/7/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 6/7/2024 due to a substantial increase in the valuation index and volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 6/7/2024 due to a substantial increase in the valuation index and volatility index.
E
Sell
5/23/2024Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 5/23/2024 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 5/23/2024 due to a decline in the volatility index.
E
Sell
4/11/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 4/11/2024 due to an increase in the solvency index and volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 4/11/2024 due to an increase in the solvency index and volatility index.
E
Sell
3/27/2024Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 3/27/2024 due to a decline in the solvency index and volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 3/27/2024 due to a decline in the solvency index and volatility index.
E
Sell
3/4/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 3/4/2024 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 3/4/2024 due to an increase in the volatility index.
E
Sell
2/15/2024Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 2/15/2024 due to a decline in the total return index, volatility index and growth index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 2/15/2024 due to a decline in the total return index, volatility index and growth index.
E
Sell
1/31/2024Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 1/31/2024 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 1/31/2024 due to an increase in the volatility index and total return index.
E
Sell
1/16/2024Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 1/16/2024 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 1/16/2024 due to a decline in the volatility index.
E
Sell
12/28/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 12/28/2023 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 12/28/2023 due to an increase in the volatility index.
E
Sell
12/7/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 12/7/2023 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 12/7/2023 due to a decline in the volatility index.
E
Sell
11/21/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 11/21/2023 due to an increase in the solvency index, volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 11/21/2023 due to an increase in the solvency index, volatility index and total return index.
E
Sell
11/15/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 11/15/2023 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 11/15/2023 due to a decline in the volatility index.
E
Sell
10/31/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 10/31/2023 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 10/31/2023 due to an increase in the volatility index.
E
Sell
10/13/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 10/13/2023 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 10/13/2023 due to a decline in the volatility index.
E
Sell
10/5/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 10/5/2023 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 10/5/2023 due to an increase in the volatility index and total return index.
E
Sell
9/20/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 9/20/2023 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 9/20/2023 due to a decline in the volatility index.
E
Sell
9/1/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 9/1/2023 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 9/1/2023 due to an increase in the volatility index.
E
Sell
8/15/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 8/15/2023 due to a decline in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 8/15/2023 due to a decline in the volatility index.
E
Sell
8/11/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 8/11/2023 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to E+ from E on 8/11/2023 due to an increase in the volatility index.
E
Sell
7/27/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 7/27/2023 due to a substantial decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.2 to 0.01, and debt to equity increased from -0.29 to -0.24.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E from E+ on 7/27/2023 due to a substantial decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.2 to 0.01, and debt to equity increased from -0.29 to -0.24.
E
Sell
3/14/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 03/14/2023.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/21/2022Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 11/21/2022 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0991 to -$0.252, and total revenue declined 86.96% from $57.5 to $7.5.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 11/21/2022 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0991 to -$0.252, and total revenue declined 86.96% from $57.5 to $7.5.
D
Sell
11/15/2022Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 11/15/2022 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 11/15/2022 due to an increase in the volatility index.
D
Sell
10/28/2022Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 10/28/2022 due to a significant decline in the solvency index, growth index and volatility index. The quick ratio declined from 0.27 to 0.07, and earnings per share declined from -$0.0989 to -$0.0991.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 10/28/2022 due to a significant decline in the solvency index, growth index and volatility index. The quick ratio declined from 0.27 to 0.07, and earnings per share declined from -$0.0989 to -$0.0991.
D
Sell
5/18/2022Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/18/2022 due to a large increase in the growth index, volatility index and valuation index. EBIT increased 19.45% from -$3.64M to -$2.93M, earnings per share increased from -$0.1211 to -$0.0989, and operating cash flow increased 6.32% from -$2.73M to -$2.56M.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/18/2022 due to a large increase in the growth index, volatility index and valuation index. EBIT increased 19.45% from -$3.64M to -$2.93M, earnings per share increased from -$0.1211 to -$0.0989, and operating cash flow increased 6.32% from -$2.73M to -$2.56M.
D
Sell
5/5/2022Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/31/2022Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the growth index, total return index and volatility index. EBIT declined 50.27% from -$2.42M to -$3.64M, earnings per share declined from -$0.0809 to -$0.1211, and total revenue declined 47.82% from $96.4 to $50.3.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the growth index, total return index and volatility index. EBIT declined 50.27% from -$2.42M to -$3.64M, earnings per share declined from -$0.0809 to -$0.1211, and total revenue declined 47.82% from $96.4 to $50.3.
D
Sell
11/9/2021Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from E+ on 11/09/2021.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/18/2020Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/18/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 65.2% from -$2.73M to -$951.3, total revenue increased 31.01% from $119.3 to $156.3, and earnings per share increased from -$0.1516 to -$0.1323.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/18/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 65.2% from -$2.73M to -$951.3, total revenue increased 31.01% from $119.3 to $156.3, and earnings per share increased from -$0.1516 to -$0.1323.
D
Sell
5/4/2020Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 5/4/2020 due to a noticeable decline in the efficiency index, volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 5/4/2020 due to a noticeable decline in the efficiency index, volatility index and total return index.
D
Sell
4/15/2020Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 4/15/2020 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 4/15/2020 due to an increase in the volatility index and total return index.
D
Sell
3/30/2020Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 3/30/2020 due to a decline in the growth index and solvency index. Total revenue declined 49.62% from $236.8 to $119.3, the quick ratio declined from 0.84 to 0.59, and operating cash flow declined 16.67% from -$2.34M to -$2.73M.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 3/30/2020 due to a decline in the growth index and solvency index. Total revenue declined 49.62% from $236.8 to $119.3, the quick ratio declined from 0.84 to 0.59, and operating cash flow declined 16.67% from -$2.34M to -$2.73M.
D
Sell
1/6/2020Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 1/6/2020 due to an increase in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 1/6/2020 due to an increase in the volatility index and total return index.
D
Sell
7/5/2019Downgrade
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 7/5/2019 due to a decline in the volatility index and total return index.
Navidea Biopharmaceuticals, Inc. (NAVB) was downgraded to D- from D on 7/5/2019 due to a decline in the volatility index and total return index.
D
Sell
5/21/2019Upgraded
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/21/2019 due to a noticeable increase in the efficiency index, valuation index and growth index. Earnings per share increased from -$0.3326 to -$0.2425, net income increased 23.14% from -$3.16M to -$2.43M, and total revenue increased 14% from $119.3 to $136.
Navidea Biopharmaceuticals, Inc. (NAVB) was upgraded to D from D- on 5/21/2019 due to a noticeable increase in the efficiency index, valuation index and growth index. Earnings per share increased from -$0.3326 to -$0.2425, net income increased 23.14% from -$3.16M to -$2.43M, and total revenue increased 14% from $119.3 to $136.
D
Sell
3/29/2019Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D- from E+ on 3/29/2019 due to a large increase in the growth index, solvency index and volatility index. Debt to equity declined from 1.61 to 0.18, EBIT increased 70.4% from -$3.72M to -$1.1M, and the quick ratio increased from 1.13 to 1.63.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D- from E+ on 3/29/2019 due to a large increase in the growth index, solvency index and volatility index. Debt to equity declined from 1.61 to 0.18, EBIT increased 70.4% from -$3.72M to -$1.1M, and the quick ratio increased from 1.13 to 1.63.
E
Sell
1/3/2019Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to E+ from D- on 1/3/2019 due to a decline in the total return index and volatility index.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to E+ from D- on 1/3/2019 due to a decline in the total return index and volatility index.
D
Sell
12/13/2018Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D- from E+ on 12/13/2018 due to an increase in the total return index and valuation index.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D- from E+ on 12/13/2018 due to an increase in the total return index and valuation index.
E
Sell
11/21/2018Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to E+ from D- on 11/21/2018 due to a noticeable decline in the efficiency index, solvency index and valuation index. Net income declined 59.63% from -$2.39M to -$3.82M, debt to equity increased from 1.04 to 1.61, and total capital declined 16.3% from $4.99M to $4.17M.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to E+ from D- on 11/21/2018 due to a noticeable decline in the efficiency index, solvency index and valuation index. Net income declined 59.63% from -$2.39M to -$3.82M, debt to equity increased from 1.04 to 1.61, and total capital declined 16.3% from $4.99M to $4.17M.
D
Sell
5/22/2018Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D- from D on 5/22/2018 due to a significant decline in the valuation index, growth index and solvency index. Operating cash flow declined 248.7% from -$648.1 to -$2.26M, debt to equity increased from 0.21 to 0.53, and earnings per share declined from -$0.025 to -$0.0415.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D- from D on 5/22/2018 due to a significant decline in the valuation index, growth index and solvency index. Operating cash flow declined 248.7% from -$648.1 to -$2.26M, debt to equity increased from 0.21 to 0.53, and earnings per share declined from -$0.025 to -$0.0415.
D
Sell
8/14/2017Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 8/14/2017 due to a significant decline in the efficiency index, total return index and growth index. Operating cash flow declined 108.54% from $66.34M to -$5.67M, earnings per share declined from $0.5165 to -$0.0326, and net income declined 106.06% from $85.58M to -$5.19M.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 8/14/2017 due to a significant decline in the efficiency index, total return index and growth index. Operating cash flow declined 108.54% from $66.34M to -$5.67M, earnings per share declined from $0.5165 to -$0.0326, and net income declined 106.06% from $85.58M to -$5.19M.
D
Sell
12/12/2016Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D+ from C- on 12/12/2016 due to a decline in the total return index.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D+ from C- on 12/12/2016 due to a decline in the total return index.
C
Hold
11/23/2016Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to C- from D+ on 11/23/2016 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 722.48% from $322.9 to $2.66M, EBIT increased 679.03% from -$580 to $3.36M, and earnings per share increased from -$0.043 to -$0.0004.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to C- from D+ on 11/23/2016 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 722.48% from $322.9 to $2.66M, EBIT increased 679.03% from -$580 to $3.36M, and earnings per share increased from -$0.043 to -$0.0004.
D
Sell
9/30/2016Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 9/30/2016 due to a significant increase in the efficiency index.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 9/30/2016 due to a significant increase in the efficiency index.
D
Sell
3/11/2016Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the total return index and volatility index.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the total return index and volatility index.
D
Sell
11/13/2015Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 11/13/2015 due to a significant increase in the growth index, efficiency index and total return index. Total revenue increased 38.75% from $2.87M to $3.98M, and EBIT increased 13.45% from -$3.81M to -$4.32M.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 11/13/2015 due to a significant increase in the growth index, efficiency index and total return index. Total revenue increased 38.75% from $2.87M to $3.98M, and EBIT increased 13.45% from -$3.81M to -$4.32M.
D
Sell
8/13/2015Downgrade
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 8/13/2015 due to a decline in the efficiency index, growth index and solvency index. EBIT declined 51.01% from -$7.78M to -$3.81M, and debt to equity increased from -0.99 to -1.31.
Navidea Biopharmaceuticals, Inc (NAVB) was downgraded to D from D+ on 8/13/2015 due to a decline in the efficiency index, growth index and solvency index. EBIT declined 51.01% from -$7.78M to -$3.81M, and debt to equity increased from -0.99 to -1.31.
D
Sell
11/13/2014Upgraded
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 11/13/2014 due to a major increase in the growth index, valuation index and solvency index. Total revenue increased 109.37% from $1.07M to $2.25M, and debt to equity declined from -1.31 to -1.04.
Navidea Biopharmaceuticals, Inc (NAVB) was upgraded to D+ from D on 11/13/2014 due to a major increase in the growth index, valuation index and solvency index. Total revenue increased 109.37% from $1.07M to $2.25M, and debt to equity declined from -1.31 to -1.04.
OTC PK
03/13/2025 11:47AM Eastern
Quotes delayed
